Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
1.450
+0.060 (4.32%)
Oct 23, 2025, 4:00 PM EDT - Market closed
4.32%
Market Cap18.44M
Revenue (ttm)n/a
Net Income (ttm)-58.92M
Shares Out 12.81M
EPS (ttm)-14.85
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume67,544
Open1.430
Previous Close1.390
Day's Range1.410 - 1.480
52-Week Range1.250 - 145.460
Beta19,964.30
Analystsn/a
Price Targetn/a
Earnings DateSep 30, 2025

About PPCB

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the Un... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 2
Stock Exchange NASDAQ
Ticker Symbol PPCB
Full Company Profile

Financial Performance

Financial Statements

News

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

This accelerates development of our clinical pipeline and leverages Hexstone's previous investments in companies that have built digital asset treasuries.

7 days ago - GlobeNewsWire

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

This accelerates development of our clinical pipeline and leverages Hexstone's previous investments in companies that have built digital asset treasuries.

8 days ago - GlobeNewsWire

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Propanc announced its fiscal year-end following the filing of its annual 10-K report with the Securities and Exchange Commission on September 29, 2025.

16 days ago - GlobeNewsWire

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

MELBOURNE, Australia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patient...

5 weeks ago - GlobeNewsWire

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Purchase of Ethereum will enhance a multi-faceted corporate strategy of cryptocurrency exposure, pharmaceutical drug development and asset acquisition.

7 weeks ago - GlobeNewsWire

Propanc Biopharma Provides Shareholder Update

Propanc is entering a transformational stage as it prepares for the advancement of its lead asset, “PRP”, to enter a Phase 1B, First-In-Human (FIH) study

2 months ago - GlobeNewsWire

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients...

2 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer

Eight issuers listed in the US this past week, six of which were eligible for inclusion in our IPO stats, joined by two SPACs. There are no IPOs currently scheduled for the week ahead, though some sma...

2 months ago - Seeking Alpha

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patien...

2 months ago - GlobeNewsWire